Rigel Pharmaceuticals (RIGL) Stock Price, Quote & News

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a suscept...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 624 1100

Fax: 650 624 1101

Website: www.rigel.com

Address:

611 Gateway Boulevard, Suite 900, South San Francisco, United States

Springsman72 Feb. 26 at 11:26 AM

$RIGL"expected to post quarterly earnings of $1.33 per share in its upcoming report, which represents a year-over-year change of +66.3%. The consensus EPS estimate for the quarter has been revised 30.4% higher over the last 30 days to the current level. Rigel Pharmaceuticals' revenues are expected to be $69.81 million, up 21.2% from the year-ago quarter. " Zacks article quote.

0 · Reply

GO_DAWGS Feb. 26 at 10:12 AM

$RIGL Almost 90% institutional ownership.

0 · Reply

GO_DAWGS Feb. 25 at 11:42 PM

$RIGL https://x.com/i/grok/share/9b6f34a1a3b24f19a42c6ee40f91ae8d

0 · Reply

B4I4QQTRU18 Feb. 25 at 11:26 PM

$RIGL Share buy back plan needed. 50 million funding for 2026 would send the shorts to the exits. They don't need to purchase a share, everybody else will do it for them. 90% tute ownership, 21% short. Street has no confidence they can spend their 150 million in cash and growing wisely.

1 · Reply

B4I4QQTRU18 Feb. 25 at 9:45 PM

$RIGL Deeper and deeper the suspense.

2 · Reply

nirok Feb. 25 at 4:34 PM

$RIGL Rigel anticipates 2026 total revenue of approximately $275 to $290 million, including: Net product sales of approximately $255 to $265 million. Contract revenues of approximately $20 to $25 million. The company anticipates it will report positive net income for the full year 2026, while funding existing and new clinical development programs.

0 · Reply

mitgodog Feb. 25 at 3:23 PM

$RIGL Wrong direction, Again!!

1 · Reply

DosGatos Feb. 24 at 4:09 PM

$RIGL zack’s bot workin harder than raul?

1 · Reply

Springsman72 Feb. 24 at 2:57 PM

$RIGL maybe the beat down is slowing and finally ready for the usual slow crawl up into earnings meeting time.

1 · Reply

ZacksResearch Feb. 24 at 2:07 PM

$IOVA vs. $RIGL — beaten-down growth or riding the rally? 🧬 IOVA has Amtagvi sales surging, yet the stock is still down 46%, setting up a serious disconnect. Meanwhile, RIGL is coming off a strong 2025 rally. One’s a rebound play, the other’s extended momentum. Which small-cap biotech has more upside from here? Get the full breakdown 👉 https://www.zacks.com/stock/news/2874164/iova-vs-rigl-which-small-cap-biotech-has-more-upside-potential?cid=sm-stocktwits-2-2874164-teaser-34809&ADID=SYND_STOCKTWITS_TWEET_2_2874164_TEASER_34809

0 · Reply

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 3, 2026, 8:05 AM EST - 22 days ago

Rigel Appoints Michael P. Miller to the Board of Directors

Jan 26, 2026, 10:40 PM EST - 4 weeks ago

Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026

Jan 15, 2026, 3:25 AM EST - 6 weeks ago

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:05 AM EST - 6 weeks ago

Rigel Provides Business Update and 2026 Outlook

Jan 9, 2026, 8:05 AM EST - 6 weeks ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jan 7, 2026, 8:05 AM EST - 7 weeks ago

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 1, 2026, 4:41 AM EST - 2 months ago

Rigel Pharma: Formulating A Game Plan For 2026

Dec 7, 2025, 9:30 AM EST - 2 months ago

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Nov 26, 2025, 8:15 AM EST - 3 months ago

Rigel Pharma: Q3 Earnings Showcase Robust Growth

Nov 26, 2025, 8:05 AM EST - 3 months ago

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 8:05 AM EST - 3 months ago

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Nov 12, 2025, 8:05 AM EST - 3 months ago

Rigel to Present at the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:06 PM EST - 4 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 4 months ago

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:05 AM EST - 4 months ago

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Oct 30, 2025, 2:20 PM EDT - 4 months ago

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Oct 29, 2025, 8:05 AM EDT - 4 months ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Oct 8, 2025, 8:05 AM EDT - 5 months ago

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Sep 25, 2025, 10:53 PM EDT - 5 months ago

Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion

Aug 26, 2025, 8:05 AM EDT - 6 months ago

Rigel to Participate in Upcoming September Investor Conferences

Aug 15, 2025, 5:20 PM EDT - 6 months ago

Overlooked Stock: RIGL Nearly Doubles Stock in August

Aug 15, 2025, 12:00 PM EDT - 6 months ago

The Big 3: OPEN, RIGL, JOBY

JOBY OPEN

Aug 13, 2025, 11:58 PM EDT - 7 months ago

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

Aug 5, 2025, 8:02 PM EDT - 7 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 7 months ago

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:05 AM EDT - 7 months ago

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

May 28, 2025, 8:05 AM EDT - 9 months ago

Rigel to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:20 PM EDT - 9 months ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 7, 2025, 6:16 PM EDT - 10 months ago

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 6, 2025, 11:13 PM EDT - 10 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 10 months ago

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:05 AM EDT - 10 months ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Apr 4, 2025, 3:31 PM EDT - 11 months ago

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Mar 27, 2025, 8:05 AM EDT - 11 months ago

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 10, 2025, 8:05 AM EDT - 1 year ago

Rigel Appoints Mark W. Frohlich, M.D.

Mar 4, 2025, 11:29 PM EST - 1 year ago

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:01 PM EST - 1 year ago

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:05 AM EST - 1 year ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Jan 22, 2025, 8:05 AM EST - 1 year ago

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 13, 2025, 8:05 AM EST - 1 year ago

Rigel Provides Business Update and 2025 Outlook

Jan 9, 2025, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 8, 2025, 8:05 AM EST - 1 year ago

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 8:30 AM EST - 1 year ago

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Dec 9, 2024, 12:02 PM EST - 1 year ago

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Dec 2, 2024, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Nov 12, 2024, 8:05 AM EST - 1 year ago

Rigel to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 10:25 PM EST - 1 year ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:05 AM EST - 1 year ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Springsman72 Feb. 26 at 11:26 AM

0 · Reply

GO_DAWGS Feb. 26 at 10:12 AM

$RIGL Almost 90% institutional ownership.

0 · Reply

GO_DAWGS Feb. 25 at 11:42 PM

$RIGL https://x.com/i/grok/share/9b6f34a1a3b24f19a42c6ee40f91ae8d

0 · Reply

B4I4QQTRU18 Feb. 25 at 11:26 PM

1 · Reply

B4I4QQTRU18 Feb. 25 at 9:45 PM

$RIGL Deeper and deeper the suspense.

2 · Reply

nirok Feb. 25 at 4:34 PM

0 · Reply

mitgodog Feb. 25 at 3:23 PM

$RIGL Wrong direction, Again!!

1 · Reply

DosGatos Feb. 24 at 4:09 PM

$RIGL zack’s bot workin harder than raul?

1 · Reply

Springsman72 Feb. 24 at 2:57 PM

$RIGL maybe the beat down is slowing and finally ready for the usual slow crawl up into earnings meeting time.

1 · Reply

ZacksResearch Feb. 24 at 2:07 PM

0 · Reply

ZacksResearch Feb. 24 at 1:07 PM

$IOVA vs. $RIGL: Which biotech stock is the better bet? 🤔 IOVA's Amtagvi sales surged 183% YoY in the first nine months of 2025, with a promising pipeline and potential FDA filing for NSCLC indication. Despite setbacks, there's growth potential ahead. Meanwhile, RIGL's overall product sales are expected to rise 60% in 2025, but Tavalisse faces tough competition from Big Pharma. See what makes IOVA a potentially safer pick 👉 https://www.zacks.com/stock/news/2874164/iova-vs-rigl-which-small-cap-biotech-has-more-upside-potential?cid=sm-stocktwits-2-2874164-body-34807&ADID=SYND_STOCKTWITS_TWEET_2_2874164_BODY_34807

0 · Reply

nirok Feb. 23 at 5:50 PM

$RIGL By next month Rigl will have over $170 million in cash. What are they going to do with this money?we know end of 4Q over 157 million ,but next month will be the end of 1Q,so about 172 million that is lots cash.

3 · Reply

nirok Feb. 23 at 4:42 PM

$RIGL i wish i could buy more today but had only for 190 shares.

0 · Reply

Namhguab Feb. 23 at 3:32 PM

$RIGL shorts looking for shares again I see.. not taking mine so have fun looking and sitting on those positions

1 · Reply

Nosh Feb. 22 at 10:01 PM

$RIGL Finding the funds...like the trendline here for a small position.

0 · Reply

QuarterlyTrader Feb. 20 at 1:51 PM

$RIGL is the pre earning beat down already finished? Something feels a wee bit different this week as we get closer to ER.

1 · Reply

BillionerOfKing Feb. 20 at 12:42 PM

$RIGL Current Stock Price: $36.61 Contracts to trade: $37.0 RIGL Feb 20 2026 Call Entry: $0.35 Exit: $0.58 ROI: 66% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

B4I4QQTRU18 Feb. 19 at 11:38 PM

$RIGL More stock options for the gang. These do appear to be their annual merit shares. It is a considerable amount. Raul got 53K. 1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. https://ir.stockpr.com/rigel/sec-filings-email/content/0000905148-26-000955/form4.html

2 · Reply

B4I4QQTRU18 Feb. 19 at 11:23 PM

$RIGL look at that green 4Q candle by hedge funds. Raul, give us our spark and this thing will be on fire. Bring in our 4th molecule before CC on 3/3.

1 · Reply

nirok Feb. 19 at 9:34 PM

$RIGL Rigel Pharmaceuticals (RIGL) is primarily held by institutional investors, with BlackRock, Inc. (approx. 9.5%), State Street Global Advisors (approx. 6%), and The Vanguard Group (approx. 5.7%) holding the largest positions. As of late 2025, over 300 institutional entities hold around 17 million shares, with significant stakes also held by Armistice Capital and Goldman Sachs, and there is only 18 million shares outstanding that is remarkable .

3 · Reply

QuarterlyTrader Feb. 19 at 9:22 PM

$RIGL don’t be shocked if they try to push this down before earnings. If you watched last time they hammered it in the last 5 min before earning report after the bell. Maybe they do t have enough juice left because people are holding there shares. I put a sell order in of $99 on all my shares so no short will touch them. Consider doing the same.

2 · Reply

DosGatos Feb. 19 at 1:52 AM

$RIGL Zack’s is a joke be gone please!

0 · Reply

Market Cap	626.39M
Revenue (ttm)	179.28M
Net Income (ttm)	17.49M
EPS (ttm)	N/A
PE Ratio	5.55
Forward PE	8.62
Profit Margin	9.76%
Debt to Equity Ratio	0.25

Volume	457,000
Avg Vol	424,520
Day's Range	N/A - N/A
Shares Out	18.15M
Stochastic %K	28%
Beta	1.11
Analysts	Sell
Price Target	$51.60